11月24日，中恒集团盘中上涨2.28%，截至09:52，报2.69元/股，成交3694.26万元，换手率0.43%，总市 值85.95亿元。 分红方面，中恒集团A股上市后累计派现29.41亿元。近三年，累计派现6874.28万元。 机构持仓方面，截止2025年9月30日，中恒集团十大流通股东中，南方中证1000ETF（512100）位居第 五大流通股东，持股2423.75万股，相比上期减少64.15万股。香港中央结算有限公司位居第六大流通股 东，持股2408.94万股，相比上期减少142.43万股。汇添富中证中药ETF（560080）位居第七大流通股 东，持股1655.74万股，为新进股东。华夏中证1000ETF（159845）位居第八大流通股东，持股1440.69 万股，为新进股东。广发中证1000ETF（560010）位居第十大流通股东，持股1114.05万股，为新进股 东。 责任编辑：小浪快报 资料显示，广西梧州中恒集团股份有限公司位于广西梧州工业园区工业大道1号，成立日期1993年7月28 日，上市日期2000年11月30日，公司主营业务涉及对医药、能源、基础设施、城市公用事业、酒店旅游 业、物流业 ...

Core Insights - The expert consensus on the prevention and treatment of vascular diseases and their target organ damage has been officially released, with the core product of Wuzhou Pharmaceutical, an affiliate of Zhongheng Group, namely the injectable Thrombus-Resolving Agent (freeze-dried), being included as a recommended medication for "activating blood circulation and removing blood stasis" [1][2] - The injectable Thrombus-Resolving Agent received the highest level of evidence (Ia) and an A-level recommendation, establishing it as a significant choice in the field of traditional Chinese medicine for multi-target organ protection against vascular diseases [1] Industry and Company Summary - The expert consensus was guided by academicians Ge Junbo and Chen Keji, involving 43 authoritative experts from 19 provinces, covering key areas of vascular diseases such as cardiovascular, cerebrovascular, renal, ocular, peripheral vascular, and endocrine [1] - The injectable Thrombus-Resolving Agent's clinical value is highlighted by its indications, which include coronary heart disease angina, myocardial infarction, cerebral infarction, retinal vein occlusion, and deep vein thrombosis of the lower limbs, addressing the treatment needs of multiple target organs [1][2] - The inclusion of the injectable Thrombus-Resolving Agent in the expert consensus not only recognizes its clinical efficacy but also marks a significant step in Wuzhou Pharmaceutical's academic positioning in the field of vascular disease treatment, reinforcing its industry status in traditional Chinese medicine [2]

Core Viewpoint - Recently, Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, successfully won bids for multiple core products in national and Guangdong alliance drug procurement, showcasing the company's market competitiveness and laying a solid foundation for future market expansion [1][2] Group 1: National Drug Procurement - Lai Mei Pharmaceutical's Nicorandil tablets (5mg) were selected in the 11th batch of national drug centralized procurement, marking a significant entry into the mainstream medical market by 2025 [1] - The selection of Nicorandil tablets will provide strong support for sales and meet broader clinical needs, injecting new momentum into Lai Mei Pharmaceutical's high-quality development [1] Group 2: Guangdong Alliance Drug Procurement - Lai Mei Pharmaceutical achieved success in multiple rounds of Guangdong alliance drug procurement, with selected products covering various fields including anti-infective drugs, specialty medications, and basic infusion solutions [1] - The successful procurement results for drugs like Clindamycin injection and Triptorelin acetate injection further demonstrate the company's strong performance in the market [1] - In the procurement for common and chronic disease medications, Lai Mei Pharmaceutical's Cefoperazone dry suspension (50mg) was also successfully selected, enhancing drug accessibility [2] Group 3: Company Strength and Market Impact - The dual breakthroughs in national and provincial procurement reflect Lai Mei Pharmaceutical's comprehensive strength [2] - The selection of multiple products in centralized procurement accelerates the clinical accessibility of quality drugs, benefiting a wider patient population and reinforcing the company's brand influence in niche markets [2]

Overview of Shareholding Structure Adjustment - Guangxi Investment Group signed an agreement with its subsidiary Guangxi Investment Group Financial Holdings Co., Ltd. to adjust the shareholding structure by increasing capital and transferring shares of Wuzhou Zhongheng Group Co., Ltd. [1] - The adjustment involves Guangxi Investment Group transferring 859,343,587 shares of Wuzhou Zhongheng, representing 26.89% of its total shares, to Guangxi Investment Group Financial Holdings [1] Impact on Guohai Securities - As of the announcement date, Wuzhou Zhongheng holds 245,478,844 shares of Guohai Securities, accounting for 3.84% of the total shares, while Guangxi Investment Group Financial Holdings holds 431,155,748 shares, representing 6.75% [2] - After the capital increase, Guangxi Investment Group Financial Holdings will indirectly control Wuzhou Zhongheng's shares in Guohai Securities, resulting in a total holding of 676,634,592 shares, which is 10.60% of the total shares [2] Share Transfer Registration - The share transfer registration for the 859,343,587 shares has been completed, confirming Guangxi Investment Group Financial Holdings as the controlling shareholder of Wuzhou Zhongheng [3] - Following the adjustment, Guangxi Investment Group Financial Holdings remains a major shareholder and the second-largest shareholder of Guohai Securities [3] Other Relevant Information - The shareholding adjustment will not change the actual controller of Guohai Securities or its control rights [3] - Wuzhou Zhongheng has committed to a lock-up period for its shares in Guohai Securities until November 17, 2028, which remains unaffected by the shareholding adjustment [4]

Core Points - On November 3, 2025, Zhongheng Group announced that its controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment"), signed a capital increase agreement and share transfer agreement with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment will transfer 859,343,587 shares (26.89% of the total share capital) to Guangxi Financial Holding for a total consideration of RMB 4,070.536 million, equivalent to RMB 4.74 per share [1] - The transaction has been confirmed by the Shanghai Stock Exchange and the share transfer registration was completed on October 31, 2025, resulting in Guangxi Financial Holding becoming the new controlling shareholder of Zhongheng Group, while the actual controller remains the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]

Core Points - On November 3, 2025, Laimei Pharmaceutical announced that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment Group"), signed an "Equity Increase Agreement" and "Share Transfer Agreement" with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment Group plans to increase capital by transferring 859,343,587 shares (26.89% of the total share capital) of its holding in the controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (referred to as "Zhongheng Group"), to Guangxi Financial Holding [1] - The transfer has been confirmed for compliance by the Shanghai Stock Exchange and received a "Securities Transfer Registration Confirmation" from China Securities Depository and Clearing Co., Ltd. on November 3, 2025, with the transfer date being October 31, 2025 [1] - After the completion of the share transfer registration, Guangxi Financial Holding will become the indirect controlling shareholder of the company, while Zhongheng Group remains the direct controlling shareholder, and the actual controller of the company is still the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]

Core Viewpoint - Guangxi Investment Group, the actual controller of Guohai Securities, signed an agreement with its subsidiary Guangtou Jinkong to increase capital by transferring 858 million shares of Zhongheng Group, representing 26.89% of the total share capital [1] Group 1 - As of the announcement date, Zhongheng Group and Guangtou Jinkong held 3.84% and 6.75% of Guohai Securities' shares, respectively [1] - On November 3, the relevant shares were successfully transferred, resulting in Guangtou Jinkong becoming the controlling shareholder of Zhongheng Group [1] - Following the adjustment, Guangtou Jinkong directly or indirectly holds 10.60% of Guohai Securities, maintaining its status as a major and second shareholder [1] Group 2 - The adjustment does not affect the actual controller and control rights of the company [1] - A portion of Zhongheng Group's shares will be locked until November 17, 2028 [1]

一、协议转让前期基本情况 重要内容提示： 2025 年 9 月 26 日，广西梧州中恒集团股份有限公司（以下简称"公司"或 "中恒集团"）的控股股东广西投资集团有限公司（以下简称"广投集团"）与 广西投资集团金融控股有限公司（以下简称"广投金控"）签署了《增资协议》 《股份转让协议》，广投集团以其所持有的公司 859,343,587 股（占公司总股本的 26.89%）无限售条件流通股股份对其控股公司广投金控进行增资扩股。广投集团 持有中恒集团股份数量为 859,343,587 股，增资总计作价人民币 407,053.60 万元 （折合每股人民币 4.74 元），其中 296,621.438461 万元计入广投金控注册资本， 110,432.161539 万元计入广投金控资本公积后，再向广投金控原股东等比例转增 资本。 本次协议转让事项已经上海证券交易所合规性确认，并于 2025 年 11 月 3 日 取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》，过户日期 为 2025 年 10 月 31 日，过户数量为 859,343,587 股（占公司股份总数的 26.89%）， 股份性质为无限售条件流通股 ...

1 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-90 广西梧州中恒集团股份有限公司 关于控股子公司参加第十一批全国药品集中采购 拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）的控 股子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）参加了由国家组 织药品联合采购办公室（简称"联采办"）组织开展的第十一批全国药品集中采 购投标工作。根据联采办发布的《全国药品集中采购拟中选结果公示》，莱美药 业产品尼可地尔片拟中选本次集中采购，现将相关情况公告如下： 注：该产品的拟中选价格、拟中选数量及拟供应省区均以联采办发布的最终数据为准。 二、本次拟中选对公司的影响 莱美药业上述拟中选产品尼可地尔片（规格：5mg）于 2025 年 9 月取得国 家药品监督管理局核准签发的《药品注册证书》，具体内容详见公司于 2025 年 9 月 18 日在上海证券交易所网站披露的《广西梧州中恒集团股份有限公司关于 控股子公司获得药品注册证书的公告》（公告 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-89 广西梧州中恒集团股份有限公司 关于拟注销南宁中恒双钱实业有限公司的公告 本次注销事项不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《上海证券交易所股票上市规则》《公司章程》等相 关规定，公司本次注销事项在董事会审批权限范围内，无需提交股东大会审议。 具体情况如下： 一、拟注销主体基本情况 （一）基本情况 | 企业名称 | 南宁中恒双钱实业有限公司 | | --- | --- | | 统一社会信用代码 | 91450100340314655M | | 法定代表人 雷晓刚 | | | 类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 成立日期 2015-6-9 | | | 注册资本 5,000.00 | 万元 | | 登记机关 | 南宁市市场监督管理局经济技术开发区分局 | | 住所 | 南宁市高岭路 号 号车间 100 1 | | 经营范围 | 食品的生产及销售（凭许可证在有效期内开展经营活动，具体项目以审 | | | 批部门批准的为准）；自营和代理一般经营项目商品和技术的进出口业 | | ...